Renal cancer (2021 – CME) – online course
Description
Authors: F. Deschamps and M. Tsitskari
Reviewers: M. Calandri, L. Crocetti, M. Das, P. Freyhardt, C. Nice and O. van Delden
This course corresponds to chapter 2.2.5.3 Non-Vascular Interventional Oncology in the European Curriculum and Syllabus for IR.
Abstract
An increasing number of renal cell carcinomas (RCCs) have been diagnosed in recent years, in part due to incidental detection from the increased use of cross-sectional imaging. The management of small, asymptomatic RCC generates significant controversy. Historically, total nephrectomy has been the treatment of choice for patients. Preservation of renal function however is paramount in patients with RCC with comorbid conditions, multiple RCCs, and/or heritable renal cancer syndromes. This need has driven the development of minimally invasive therapeutic alternatives. Although partial nephrectomy is considered the primary treatment, percutaneous ablation is an alternative nephron-sparing approach in these patients.
Learning objectives
- Learn and understand tumour biology and pathology
- Know the relevant tumour classifications and staging
- Know the different IR treatment options for the treatment of small RCCs and their outcomes
- Know which device, probe, probe size and positions relevant to the tumour, location and size
- Recognise the imaging appearances and end points during treatment, i.e. progress of the ice ball and when to stop
- Learn how to minimise the risk of complications
- Recognise and treat potential complications
Further information
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for IR and corresponds to chapter 2.2.5.3 Non-Vascular Interventional Oncology.
The format of the course is interactive and easy to use, including texts, graphics, videos and a quiz to support your learning. The course duration is around one hour and is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1 European CME credit (ECMEC). The CME accreditation for this course will expire on June 16, 2023. A non-CME accredited version of the course will remain available for two more years.
The enrolment period of this course is set to 90 days and may be extended throughout the year with a valid All-Access Pass.
The CME certificate will be available in the myCIRSE area past the enrolment period if the course is completed before June 16, 2023.
Release date: June 2021
